Core Viewpoint - Deyuan Pharmaceutical reported a robust performance in 2025, achieving significant revenue and profit growth despite challenging market conditions [1] Financial Performance - The company achieved an operating revenue of 1.058 billion yuan in 2025, representing a year-on-year increase of 21.8% [1] - The net profit attributable to shareholders was approximately 237 million yuan, reflecting a year-on-year growth of 33.87% [1] Strategic Response - In response to intense market competition, regulatory changes, and price reductions from centralized procurement, the company implemented strategies to expand market share and optimize product sales structure [1] - The company focused on the collaborative development of both generic and innovative drug pipelines, alongside meticulous cost control measures to ensure steady growth in overall business performance [1]